文献速递胸部腹部技术与安全CT

基于TotalSegmentator体成分分析对免疫治疗肿瘤患者生存的预后价值

Prognostic value of body composition analysis in cancer patients treated with immunotherapy: a systematic evaluation of TotalSegmentator-based biomarkers.
PubMed 文献 · Radiol Med · 2026-08-18

本研究回顾性纳入357例接受免疫治疗的晚期非小细胞肺癌或黑色素瘤患者,利用TotalSegmentator v2.8.0自动分割治疗前胸腹盆CT。分析骨骼肌、内脏脂肪、皮下脂肪及肌内脂肪的体积与面积参数,发现基于CAP容积的体成分指标与总生存相关,容积法预后价值优于单一层面面积法。

要点

  • CT CAP容积法体成分参数与免疫治疗总生存相关,优于单一层面面积指标。
  • L3层面与CAP容积的体成分参数相关性高(r=0.87–0.98)。
  • 肌肉-骨比值和骨骼肌指数预测生存的c指数相近(0.616与0.618)。

核心结论

  • TotalSegmentator v2.8.0自动分割的CT CAP容积体成分参数与免疫治疗总生存相关。
  • 整合各组织数量与密度指标的多参数模型预测效能最佳(c指数0.621)。
  • 容积法体成分分析可用于常规影像预后评估,辅助优化免疫治疗决策。

研究设计与样本

  • 回顾性研究,共357例晚期非小细胞肺癌或黑色素瘤患者。
  • 采用治疗前胸腹盆CT(CT CAP),使用TotalSegmentator v2.8.0进行自动分割。
  • 量化T1至骶骨范围的骨骼肌、内脏脂肪、皮下脂肪、肌内脂肪体积及T4、L3层面面积。
  • 同时测量软组织密度、身高标准化指数及组织-骨比值。
  • 生存分析采用Kaplan-Meier曲线、log-rank检验及年龄性别校正的多变量Cox回归和c指数。

关键影像表现/征象

  • L3层面与CAP容积的体成分参数呈强相关(r=0.87–0.98)。
  • 短生存组与长生存组间所有CAP容积体成分指标均有显著差异。
  • L3层面肌内脂肪面积身高平方值和T4层面内脏脂肪面积身高平方值在两组间无显著差异(p=0.068和p=0.169)。
  • 肌肉-骨比值与骨骼肌指数的Cox模型c指数相近(0.616与0.618)。

诊断标准与关键数值

  • 一年死亡率为52%(95% CI 47–58%),五年死亡率为84%(95% CI 80–88%)。
  • 肌肉-骨比值Cox模型c指数为0.616,骨骼肌指数Cox模型c指数为0.618。
  • 整合各组织数量与密度指标的最佳模型c指数为0.621。
  • L3层面肌内脂肪面积身高平方值p=0.068,T4层面内脏脂肪面积身高平方值p=0.169。

临床应用与阅片要点

  • 日常阅片可采用TotalSegmentator自动分割CT CAP容积法进行体成分预后评估。
  • 容积法体成分指标比单一层面面积指标更能区分免疫治疗患者的生存差异。
  • 整合多组织数量与密度指标可提高对免疫治疗总生存的预测效能。

局限性

  • 回顾性研究设计,仅纳入晚期非小细胞肺癌和黑色素瘤两种瘤种。
  • 单中心数据,结果外推至其他癌种或免疫治疗场景需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Body composition parameters offer objective, imaging-derived prognostic biomarkers, valuable in the context of oncological diseases. This study evaluated the predictive value for overall survival of body composition parameters automatically derived via TotalSegmentator in cancer patients undergoing immunotherapy.

MATERIALS AND METHODS: We retrospectively included pretreatment CT of chest, abdomen, and pelvis (CT CAP) of patients with advanced non-small cell lung cancer or melanoma. Following TotalSegmentator v2.8.0 segmentation, skeletal muscle (SM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intramuscular adipose tissue (IMAT) volumes from T1 to the sacrum and areas at the T4, L3 levels were quantified, alongside soft tissue densities. Pearson correlations, height-normalized indices, and tissue-to-bone ratios were calculated. Survival was analyzed using Kaplan-Meier curves, log-rank tests, and multivariable age/sex-adjusted Cox regression and the c-index.

RESULTS: Of the 357 patients, the one-year and five-year mortality rates were 52% (95% CI 47-58%) and 84% (95% CI 80-88%), respectively. Body composition parameters at the L3 level and in CAP volume were strongly correlated (r = 0.87-0.98). Differences between short and long survival groups were significant for all CAP volume-based body composition biomarkers, while area-based IMAT and VAT height-squared values were not discriminative at the L3 and T4 levels, respectively (p = 0.068 and p = 0.169). Cox models with muscle-to-bone ratio and SM index yielded similar c-indexes (0.616 and 0.618). The best c-index was achieved integrating quantity and density biomarkers of all tissues (0.621).

CONCLUSION: TotalSegmentator v2.8.0-derived CT CAP volume-based parameters were associated with immunotherapy overall survival, enabling routine volumetric prognostication to optimize treatment.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Yang, Lawrance, Bône, et al. Prognostic value of body composition analysis in cancer patients treated with immunotherapy: a systematic evaluation of TotalSegmentator-based biomarkers. Radiol Med. 2026. PMID: 42613494. doi:10.1007/s11547-026-02266-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。